These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 14732923)

  • 21. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
    Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
    Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
    Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
    Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
    Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
    Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
    Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
    Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
    Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.
    Smith ML; Arch R; Smith LL; Bainton N; Neat M; Taylor C; Bonnet D; Cavenagh JD; Andrew Lister T; Fitzgibbon J
    Br J Haematol; 2005 Feb; 128(3):318-23. PubMed ID: 15667533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
    Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia.
    Inokuchi K; Yamaguchi H; Hanawa H; Tanosaki S; Nakamura K; Tarusawa M; Miyake K; Shimada T; Dan K
    Clin Cancer Res; 2002 Jun; 8(6):1882-8. PubMed ID: 12060632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
    Bruserud Ø; Hovland R; Wergeland L; Huang TS; Gjertsen BT
    Haematologica; 2003 Apr; 88(4):416-28. PubMed ID: 12681969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
    Groves MJ; Sales M; Baker L; Griffiths M; Pratt N; Tauro S
    Cancer Genet; 2011 Jan; 204(1):39-44. PubMed ID: 21356190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
    Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
    Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
    J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation analysis of SBDS in pediatric acute myeloblastic leukemia.
    Majeed F; Jadko S; Freedman MH; Dror Y
    Pediatr Blood Cancer; 2005 Dec; 45(7):920-4. PubMed ID: 16007594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.
    Galimberti S; Rossi A; Palumbo GA; Morabito F; Guerrini F; Vincelli I; Fazzi R; Santini V; Petrini M
    Anticancer Res; 2003; 23(4):3419-26. PubMed ID: 12926083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.